Takasago International Corporation applied for the tender offer for 420,534 shares of Hisamitsu Pharmaceutical Co., Inc. at 6,082 yen per share, totaling 2,557 million yen, and expects to record an extraordinary profit of 2,408 million yen in the fiscal year ending March 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4914","jir_company_name":"Takasago International Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-01-16","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4914-20260116-01.pdf","jir_short_summary":"Takasago International Corporation applied for the tender offer for 420,534 shares of Hisamitsu Pharmaceutical Co., Inc. at 6,082 yen per share, totaling 2,557 million yen, and expects to record an extraordinary profit of 2,408 million yen in the fiscal year ending March 2026.","jir_summary":"### Overview of Tender Offer Application\nTakasago International Corporation's Board of Directors resolved to apply its entire holding of 420,534 common shares of Hisamitsu Pharmaceutical Co., Inc. to the tender offer conducted by Taiyo Kosan Co., Ltd. The planned purchase price is 6,082 yen per share, with a total planned sale amount of 2,557 million yen. The application decision is based on the endorsement of the tender offer by Hisamitsu Pharmaceutical Co., Inc.'s Board of Directors and the reasonableness of the conditions.\n\n### Outlook and Impact\nIf this tender offer is successful and all shares are sold, Takasago International Corporation expects to record an extraordinary profit of 2,408 million yen as investment securities sale gains in both standalone and consolidated financial results for the fiscal year ending March 2026. The tender offer period is from January 7, 2026, to February 19, 2026, with the settlement start date on February 27.","jir_financial_highlights":"Number of shares applied: 420,534 shares (Same as shares held before application)\nPlanned purchase price (per share): 6,082 yen (Unknown)\nPlanned total sale amount: 2,557 million yen (Unknown)\nExpected recognition of extraordinary profit: 2,408 million yen (Unknown)","jir_category":"","jir_hashtags":"#TakasagoInternational, #TenderOffer, #TOB, #InvestmentSecuritiesSaleGain, #JapaneseStocks","jir_key_figures":"Number of shares applied: 420,534 shares (entire holding)\nPlanned purchase price: 6,082 yen \/ share\nExpected recognition of extraordinary profit: 2,408 million yen (Fiscal Year ending March 2026)","jir_meta_title":"Takasago International to Apply for Tender Offer of 420,534 Hisamitsu Pharmaceutical Shares and Expect 2,408 Million Yen Extraordinary Profit","jir_meta_description":"Takasago International Corporation applies for the tender offer for 420,534 shares of Hisamitsu Pharmaceutical Co., Inc. at 6,082 yen per share. It expects to record 2,408 million yen as investment securities sale gains in the fiscal year ending March 2026.","jir_og_title":"Takasago International Announces Tender Offer Application for Hisamitsu Pharmaceutical Shares and Expected Extraordinary Profit Recognition","jir_og_description":"Takasago International Corporation has applied for the tender offer for 420,534 shares of Hisamitsu Pharmaceutical and expects to record an extraordinary profit of 2,408 million yen in the fiscal year ending March 2026.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9256,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"tender_offer","footnotes":""},"sector":[],"importance":[],"class_list":["post-19403","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n